CTIS2024-512621-88-00招募中1 期
Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and safety of reparixin as add-on therapy to standard of care in adult patients with Acute Respiratory Distress Syndrome (RESPIRATIO) - REP0122
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Signed Informed Consent, according to local guidelines and regulations., Male and female adults (>18 years old)., Mechanically ventilated (invasive) patients with PaO2/FIO2 ratio = 200 in the presence of PEEP of =5 cm H2O., Respiratory failure not fully explained by cardiac failure or fluid overload (if acute Congestive Heart Failure exacerbation is identified as part of the clinical picture this should be addressed effectively and as soon as possible before the patient can be enrolled)., Bilateral radiologic opacities consistent with pulmonary edema on the frontal chest x-ray (CXR) radiograph, or bilateral ground glass opacities on a chest CT scan., =48 hours from fulfilling above ARDS criteria (if a patient is transferred from a non-participating hospital to a participating site, a 12-hour period beyond the 48 hours is allowed), Females of child-bearing potential who are sexually active must be willing not to get pregnant within 30 days after the last Investigational Medicinal Product (IMP) dose and must agree to at least one of the following reliable methods of contraception: • Hormonal contraception, systemic, implantable, transdermal, or injectable contraceptives from at least2 months before the screening visit until 30 days after the last IMP dose; • A sterile sexual partner; • Abstinence. For patients unable to personally consent to the above, due to complications of acute illness and/or its treatment, assurances for the above must be given by LR and reiterated by the patient when/if she is able to do so. Female participants of non-child-bearing potential or in postmenopausal status for at least 1 year will be admitted. For all female subjects with child-bearing potential, pregnancy test results must be negative before first drug intake.
排除标准
- •Moderate-Severe chronic hepatic disease (as verified by a previously known Child-Pugh score =7). If baseline Child-Pugh score is not known, it should not be calculated while the patient is acutely ill. In that case, the patient is excluded on the basis of: ALT/AST = 3x ULN and total bilirubin > 2x ULN or ALT/AST = 5x ULN., History of: a) Documented allergy/hypersensitivity to sulfonamides, ibuprofen and other COX-1 and 2 inhibitors, and to the study product and/or its excipients. b) Lactase deficiency, galactosemia or glucose-galactose malabsorption. c) History of peptic ulcer, GI bleeding or perforation due to previous NSAID therapy., Active bleeding (excluding menses) from an uncontrolled site that cannot be definitively resolved prior to enrollment., Pregnant or lactating women., Women of childbearing potential and fertile men who do not agree to use at least one primary form of contraception during the study and up to 30 days after the last IMP dose. For patients unable to personally consent to above due to complications of acute illness and/or its treatment, assurances for the above must be given by LR and reiterated by the patient when/if he/she is able to do so., Severe chronic renal dysfunction: eGFR (2021 CKD-EPI) < 30 mL/min/1.73m2 . If baseline (chronic) renal function is not known, the patient is only excluded if in need of acute renal replacement therapy (currently on RRT or to be imminently placed on RRT)., Participation in another interventional clinical trial., Patients that are clinically determined to have a high likelihood of death within the next 24 hours based on PI's estimation., Currently receiving ECMO or high frequency oscillatory ventilation., Anticipated extubation within 24 hours of screening. (In such cases, re-screening is allowed if the patient is within the enrollment window)., Evidence of GI dysmotility as demonstrated by presence of all the following: persistent gastric distention and enteral feeding intolerability and persistent gastric residuals >500 ml)., Anticipated transfer to a hospital not participating in the trial within 72 hours of screening., Decision to withhold or withdraw life-sustaining treatment (patients may still be eligible however if they are committed to full support except cardiopulmonary resuscitation if cardiac arrest occurs).
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to evaluate the safety and efficacy of oral treatment with PBF-677 in patients with mild to moderate ulcerative colitis.EUCTR2017-003228-54-ESPaloBiofarma S.L.30
进行中（未招募）
1 期
A treatment study of ACH-0144471 in Patients with C3 Glomerulopathy (C3G).biopsy-confirmed C3 Glomerulopathy (C3G)MedDRA version: 20.0Level: PTClassification code 10077827Term: C3 glomerulopathySystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2017-000663-33-GBAchillion Pharmaceuticals, Inc.20
进行中（未招募）
不适用
A Phase II Proof-of-Concept, Randomized, Double-blind, Vehicle-controlled Study, Including an Open-label Comparison to an Active Control, To Assess the Efficacy and Safety/Tolerability of Topical Riluzole in Patients with Stable Plaque-type Psoriasis - BF-37 in stable plaque-type psoriasisEUCTR2007-007037-39-DEBiofrontera Bioscience GmbH
进行中（未招募）
1 期
A Clinical Trial to Test the Efficacy, Safety and Tolerability of Two Dosing Regimens of Cholestyramine Coated Capsules in Adults with Short Bowel SyndromeBile-acid induced diarrhea in adult patients with Short Bowel Syndrome (SBS)MedDRA version: 20.1Level: PTClassification code 10049416Term: Short-bowel syndromeSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 20.1Level: LLTClassification code 10080049Term: Bile acid diarrheaSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2018-004419-32-PLPharmascience Inc.18
进行中（未招募）
1 期
MK-7264 Phase 2a in Women with Endometriosis-related PaiModerate to severe Endometriosis-related pain (ERP)MedDRA version: 20.0Level: LLTClassification code 10014788Term: Endometriosis related painSystem Organ Class: 100000004872EUCTR2018-001098-26-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.187